FI990171A0 - New compounds and compositions for the treatment of diseases dependent on tryptase activity - Google Patents
New compounds and compositions for the treatment of diseases dependent on tryptase activityInfo
- Publication number
- FI990171A0 FI990171A0 FI990171A FI990171A FI990171A0 FI 990171 A0 FI990171 A0 FI 990171A0 FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A FI 990171 A0 FI990171 A0 FI 990171A0
- Authority
- FI
- Finland
- Prior art keywords
- compositions
- treatment
- new compounds
- diseases dependent
- tryptase activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI990171A0 true FI990171A0 (en) | 1999-01-29 |
| FI990171A FI990171A (en) | 1999-03-23 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI990171A FI990171A (en) | 1996-07-30 | 1999-01-29 | Novel compounds and compositions for the treatment of diseases related to tryptase activity |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (en) |
| JP (1) | JP2001509787A (en) |
| KR (1) | KR20000029679A (en) |
| CN (1) | CN1073103C (en) |
| AU (1) | AU733621B2 (en) |
| CA (1) | CA2262542A1 (en) |
| CZ (1) | CZ29799A3 (en) |
| EE (1) | EE9900036A (en) |
| FI (1) | FI990171A (en) |
| HU (1) | HUP0003267A3 (en) |
| LV (1) | LV12291B (en) |
| NO (1) | NO990433L (en) |
| NZ (1) | NZ333713A (en) |
| PL (1) | PL331465A1 (en) |
| SI (1) | SI9720047A (en) |
| SK (1) | SK8599A3 (en) |
| WO (1) | WO1998004537A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| ATE282607T1 (en) * | 1998-02-06 | 2004-12-15 | Max Planck Gesellschaft | TRYPTASE INHIBITORS |
| JP2002502845A (en) * | 1998-02-06 | 2002-01-29 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Tryptase inhibitor |
| WO2000014097A2 (en) * | 1998-09-04 | 2000-03-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel pyranoses |
| SI1208089T1 (en) | 1999-08-10 | 2005-04-30 | Altana Pharma Ag | Diazocin-dione derivatives and their use as tryptase inhibitors |
| WO2001019809A1 (en) * | 1999-09-14 | 2001-03-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (en) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments |
| CA2392127A1 (en) | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| CA2392121A1 (en) * | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| DK1358182T3 (en) * | 2001-01-31 | 2004-12-20 | Altana Pharma Ag | Diazocin derivatives and their use as tryptase inhibitors |
| EP1368317B1 (en) | 2001-02-21 | 2006-12-27 | Altana Pharma AG | Tryptase inhibitors |
| ES2287268T3 (en) | 2001-02-21 | 2007-12-16 | Nycomed Gmbh | TRIPTASE INHIBITORS. |
| JP2004525926A (en) * | 2001-03-15 | 2004-08-26 | アルタナ ファルマ アクチエンゲゼルシャフト | Tryptase inhibitor |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| EP1404324B2 (en) | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2002102771A1 (en) | 2001-06-19 | 2002-12-27 | Altana Pharma Ag | Tryptase inhibitors |
| BRPI0517227B8 (en) | 2004-11-04 | 2021-05-25 | Xenoport Inc | 1-{[alpha-isobutanoyloxyethoxy)carbonyl]amino methyl}-1-acetic acid extended-release tablet, and use of the tablet |
| TWI432188B (en) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases |
| US8399519B2 (en) * | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| FR3038605B1 (en) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE |
| US20200199168A1 (en) * | 2017-05-12 | 2020-06-25 | Riken | Class a gpcr-binding compound modifier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| AU683459B2 (en) * | 1993-03-12 | 1997-11-13 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| WO1995032945A1 (en) * | 1994-06-01 | 1995-12-07 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
| WO1996009297A1 (en) * | 1994-09-23 | 1996-03-28 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell inflammatory condition |
| CA2216151A1 (en) * | 1995-03-24 | 1996-10-03 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/en unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/en unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 PL PL97331465A patent/PL331465A1/en unknown
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/en not_active Application Discontinuation
- 1997-07-30 JP JP50913698A patent/JP2001509787A/en active Pending
- 1997-07-30 SI SI9720047A patent/SI9720047A/en unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/en unknown
- 1997-07-30 CN CN97196877A patent/CN1073103C/en not_active Expired - Fee Related
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 SK SK85-99A patent/SK8599A3/en unknown
- 1997-07-30 EE EEP199900036A patent/EE9900036A/en unknown
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/en not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/en unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU733621B2 (en) | 2001-05-17 |
| HUP0003267A3 (en) | 2002-02-28 |
| CN1226892A (en) | 1999-08-25 |
| LV12291B (en) | 2000-04-20 |
| JP2001509787A (en) | 2001-07-24 |
| NO990433D0 (en) | 1999-01-29 |
| LV12291A (en) | 1999-06-20 |
| EP0934293A1 (en) | 1999-08-11 |
| CZ29799A3 (en) | 1999-06-16 |
| CN1073103C (en) | 2001-10-17 |
| AU3967097A (en) | 1998-02-20 |
| SI9720047A (en) | 1999-08-31 |
| FI990171A (en) | 1999-03-23 |
| KR20000029679A (en) | 2000-05-25 |
| WO1998004537A1 (en) | 1998-02-05 |
| NO990433L (en) | 1999-03-25 |
| PL331465A1 (en) | 1999-07-19 |
| CA2262542A1 (en) | 1998-02-05 |
| EE9900036A (en) | 1999-08-16 |
| HUP0003267A2 (en) | 2001-06-28 |
| NZ333713A (en) | 2000-12-22 |
| SK8599A3 (en) | 2000-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI990171A0 (en) | New compounds and compositions for the treatment of diseases dependent on tryptase activity | |
| FI971969A (en) | Compositions for the treatment of hemorrhoids and method of use | |
| FI970918A0 (en) | Compounds and methods for the treatment of cancer | |
| FI952926A0 (en) | Procedures for the treatment and prevention of all Procedures for the treatment and prevention of allergies ergies | |
| FI971171A (en) | Compositions and methods for the treatment of mast cell inflammatory diseases | |
| FI19992398A (en) | Procedures and arrangements for the identification of heartbeats | |
| FI971568A (en) | Procedure for the treatment of resistant tumors | |
| FI971750A0 (en) | Compositions and treatment for multiple sclerosis | |
| FI954119A (en) | Procedure for the treatment of solid waste | |
| FI962370A0 (en) | Apparatus for the manufacture of tissue | |
| FI945649A0 (en) | Foerfarande och anordning Foer indentifiering av en koppling vid ventilation av en patient | |
| FI19992807A (en) | Procedure and arrangement for the elimination of disturbance | |
| FI965204A (en) | Medical use of bromelain | |
| DE69620691T2 (en) | Therapeutic agent for the treatment of hypercholesterolemia | |
| EE04055B1 (en) | Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use | |
| FI962976A0 (en) | Compositions for the treatment of galukoma containing pilocarpine and beta-blocker | |
| LV11940A (en) | The use of melatonin for the treatment of people who are dependent on grass | |
| FI963638A (en) | Procedures for the diagnosis and treatment of HIV-1 infection | |
| FI951759A (en) | The process for the preparation of 2,2-difluoketin silyl-O, S-acetals and O, S-esters of alpha, alpha-difluoro-beta-silyloxy-1,3-dioxolane-4-propanoic acid | |
| FI972694A0 (en) | New procedure for the preparation of sameridine | |
| FI102841B1 (en) | Process for the preparation of mannitol | |
| FI971378A0 (en) | Methods and intermediates for the preparation of 3-aminobenzo (b) azepinones | |
| FI964672A0 (en) | Procedure for the treatment of grain, treated grain and its use | |
| FI103753B (en) | Procedure for the treatment of concentrates | |
| NO20001897D0 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia |